NSE filing, NSE: AMBEY. Summary written from the filing by ALFA Finder's alert engine.
More from Ambey Laboratories Limited
All →Ambey Laboratories Q4 FY26 Results: Net Profit ₹2 Cr, Up 122.2% QoQ
Ambey Laboratories Limited reported revenue from operations of ₹40.5 Cr and net profit of ₹2 Cr for Q4 FY26.
- Key figure
- Net profit ₹2 Cr
Ambey Laboratories Financial Results
Ambey Laboratories Limited approved its audited FY26 financial results, reporting consolidated revenue of ₹141.54 Crore. The board also reviewed fund utilization and related party disclosures.
Ambey Laboratories Other Announcement
Dhansa Labs Limited submitted its annual SDD Compliance Certificate for the financial year 2026. This confirms regulatory adherence to SEBI insider trading monitoring requirements.
Ambey Laboratories Other Announcement
Ambey Laboratories Limited will change its name to Dhansa Labs Limited and its NSE symbol to DHANSA. The change is effective from June 01, 2026.
Ambey Laboratories Capital Structure Change
Dhansa Labs Limited allotted 3,63,043 equity shares following warrant conversions, raising ₹1.67 Crore. This exercise increases the company's paid-up capital and strengthens its equity base.
- Value
- ₹1.67 Cr
Ambey Laboratories Board Meeting Date
Ambey Laboratories scheduled a board meeting on May 29, 2026, to approve audited annual financial results. The company's trading window remains closed until May 31, 2026.
Other other announcement announcements
All →Mahindra & Mahindra Financial Services Other Announcement
Mahindra & Mahindra Financial filed its ALM statement as of September 30, 2026, submitted to RBI. It is a periodic regulatory return with no new transaction.
ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.